Jim Cramer has built a strong reputation in the industry. He’s the Mad Money host who carefully picks growth stocks that have ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer shed light on. During the lightning round, a caller sought Cramer’s ...

We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar.

Cheap Trick defends performing at Trump's Kennedy Center Honors amid backlash: 'We agreed to do it' to 'pay tribute to our lifelong brothers in KISS' ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the company has any growth potential or if PFE is a dividend play. In response ...

Pfizer’s stock rebounded from April lows yet still trades as if COVID and patent cliffs equal business ruin, despite resilient non‑COVID franchises and pipeline optionality. Q3 looked weak, with ...

Deal marks Pfizer's re-entry into obesity treatment market Pfizer shares rise 1.4%, Novo Nordisk falls 1.3% Metsera candidate MET-097i advances to late-stage trials The greenlight from Metsera's ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to ...

Pfizer has won a $10 billion deal to acquire the fast-rising obesity drug developer Metsera, ending a fierce bidding war with Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy. By Francesca Regalado The obesity drug developer ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...